Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.39 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500303 | 0.99 | KMT2A (0.40) | KMT2AMAPTALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL307960 | 0.87 | F7 (0.45) | MAPTHDAC1F10 | |
| Hydrochloric Acid SCHEMBL6544447 | 0.87 | F10 (0.42) | F10PLAU | |
| SCHEMBL5494187 | 0.86 | F7 (0.46) | MAPTHDAC1KDM4EF10 | |
| SCHEMBL5499067 | 0.86 | F10 (0.42) | F10PLAU | |
| SCHEMBL5493594 | 0.85 | RORC (0.39) | KMT2AMAPTALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL308853 | 0.82 | F10 (0.37) | KMT2AMAPTMEN1F10PLAU | |
| SCHEMBL4359370 | 0.81 | F2 (0.38) | KMT2AMAPTMEN1HDAC1F10 | |
| SCHEMBL308627 | 0.81 | F2 (0.38) | KMT2AMAPTMEN1HDAC1F10 | |
| Hydrochloric Acid SCHEMBL6544392 | 0.79 | MAPT (0.43) | KMT2AMAPTALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080226624-A1 | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect | WILEX AG (DE) | 2008-09-18 | — | — | US | claimed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | claimed |
| US-20040266766-A1 | Selective urokinase inhibitors | WILEX AG (DE) | 2004-12-30 | — | — | US | claimed |
| US-20120165287-A1 | COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT | WILEX AG (DE) | 2012-06-28 | — | — | US | disclosed |
| US-8093258-B2 | Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases | WILEX AG (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-1893185-B1 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF AMYOTROPhIC LATERAL SCLEROSIS (ALS) | WILEX AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2087885-A1 | Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases | Wilex AG (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | WILEX AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20080226624-A1 | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect | WILEX AG (DE) | 2008-09-18 | — | — | US | disclosed |
| EP-1893185-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | Wilex AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006136419-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | WILEX AG (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20040266766-A1 | Selective urokinase inhibitors | WILEX AG (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266766-A1 | Selective urokinase inhibitors | PLAU, PLAUR, SERPINE1 | GAA 1142/4885HDAC1 2231/4885KMT2A 3643/4885 |
| US-20080226624-A1 | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect | PLAU, PLAUR, SERPINE1 | GAA 865/4885HDAC1 1338/4885KMT2A 3864/4885 |
| US-20120165287-A1 | COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT | PLAU, PLAUR, SERPINE1 | GAA 865/4885HDAC1 1338/4885KMT2A 3864/4885 |
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | PLAU, SERPINE1, PLAUR | GAA 117/4885HDAC1 1374/4885KMT2A 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.